纳武利尤单抗治疗转移性透明细胞肾细胞癌:NIVOREN GETUG-AFU 26 II期研究整合生物标志物分析
该II期研究在720例VEGF受体酪氨酸激酶抑制剂治疗后进展的转移性透明细胞肾细胞癌患者中评估纳武利尤单抗,并整合组织与循环生物标志物分析。肿瘤细胞VEGF表达与更短的无进展生存和总生存强相关,循环IL-6和IL-8独立关联更短生存,而高肿瘤淋巴细胞浸润伴低中性粒细胞及非免疫基质细胞浸润者应答更佳。
要点
- 肿瘤细胞VEGF表达强关联更短PFS和OS
- 循环IL-6和IL-8独立关联更短PFS和OS
- 高淋巴细胞伴低中性粒细胞/基质浸润者应答更佳
核心结论
- 免疫和血管生成特征有助于预测纳武利尤单抗的结局。
- 循环因子是ccRCC免疫治疗活性的最佳潜在预测指标。
研究设计与样本
- 真实世界II期试验,纳入720例VEGF受体靶向治疗后进展的转移性ccRCC患者。
- 采用免疫分析和基因表达谱评估候选组织和循环生物标志物。
主要发现
- 组织架构分析显示,三级淋巴结构、CD8+淋巴细胞和CD163+巨噬细胞浸润在侵袭边缘均与更长PFS边际相关,类似免疫细胞PD-1表达。
- 肿瘤细胞缺氧相关标志物VEGF表达与更短PFS和OS强相关。
- 基于基因表达特征重现微环境组成显示,高肿瘤淋巴细胞浸润同时低中性粒细胞和非免疫基质细胞浸润的患者对纳武利尤单抗应答改善。
- 循环促肿瘤炎症相关细胞因子IL-6和IL-8独立关联更短PFS和OS。
临床怎么用
- 组织VEGF表达和循环IL-6、IL-8可能帮助识别纳武利尤单抗获益较低的患者。
- 肿瘤淋巴细胞高浸润且中性粒细胞/非免疫基质低浸润提示更佳免疫治疗应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nivolumab improved survival in patients with refractory metastatic clear-cell renal cell carcinoma (ccRCC), but no reliable biomarker of activity has been identified. We conducted a real-world phase 2 trial of nivolumab in patients progressing after one or more vascular endothelial growth factor (VEGF) receptor-directed therapies, which included an integrated translational programme. Candidate tissue and circulating biomarkers were assessed using immunoassays and gene expression profiling. Overall, 720 patients were treated, with activity and safety in line with pivotal trial data. Exploration of tissue architecture showed that the presence of tertiary lymphoid structures, CD8+ lymphocytes, and CD163+ macrophage infiltration at the invasive margin were all marginally associated with longer progression-free survival, similarly to PD-1 expression on immune cells. Expression of hypoxia-related marker VEGF on tumour cells was however strongly associated with shorter progression-free and overall survival. Recapitulation of microenvironment composition based on gene expression signatures showed that patients harbouring a high tumour lymphocyte infiltration, concomitantly to low infiltration of neutrophil and non-immune stromal cells, had improved response to nivolumab. Conversely, circulating cytokines related to protumoral inflammation interleukin (IL)-6 and IL-8 were independently associated with shorter progression-free and overall survival. Overall, immune and angiogenic features helped inform outcomes to nivolumab. Circulating factors were best potential predictors for immunotherapy activity in ccRCC.
引用
- Flippot R, Vano YA, Dalban C, et al. Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study. Eur Urol. 2025. PMID: 41224576. doi:10.1016/j.eururo.2025.09.4169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。